Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733614 · ClinicalTrials.gov registry record · Phase 2
Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD
A Phase 2 study, sponsored by Azevan Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02733614: Clinical Trial Phase 2 study, sponsored by Azevan Pharmaceuticals.
NCT02733614 is a Phase 2 study that was terminated before completion, run by Azevan Pharmaceuticals. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02733614, a Phase 2 study, was terminated before completion, sponsored by Azevan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
18-week, crossover, double-blind, randomized, placebo controlled proof-of-concept study to assess the efficacy and safety of SRX246 (160 mg bid) vs placebo in 52 adult veterans and civilians with a primary diagnosis of PTSD. Subjects will be randomly assigned in a double-blind fashion to 2 groups in a crossover design. The first group will receive SRX246 for 8 weeks followed by 8 weeks of placebo, while the second group will receive placebo for 8 weeks followed by 8 weeks of SRX246. Both groups will engage in a 7-day washout period between treatments. Subjects will be assessed at baseline and then every 2 weeks during the trial using the CAPS.
Interventions
- DRUG Placebo
- DRUG SRX246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-12 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02733614
The ClinicalTrials.gov registry entry for NCT02733614 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azevan Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02733614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02733614 about?
NCT02733614 is a clinical study titled "Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD". 18-week, crossover, double-blind, randomized, placebo controlled proof-of-concept study to assess the efficacy and safety of SRX246 (160 mg bid) vs placebo in 52 adult veterans and civilians with a primary diagnosis of PTSD. Subjects will be randomly assigned in a double-blind fashion to 2 groups in...
What is the current status of trial NCT02733614?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-12. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02733614?
The interventions under investigation include: Placebo (DRUG), SRX246 (DRUG).
Who is sponsoring clinical trial NCT02733614?
This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.